Loading...
Market
Story
Humacyte Receives FDA Approval for First-in-Class SYMVESS for Treatment of Extremity Vascular Trauma, Stock Surges 61%
Dec 20, 2024, 01:45 PM
Humacyte has received FDA approval for SYMVESS™, the first acellular tissue engineered vessel designed for the treatment of extremity vascular trauma. This innovative product serves as a bioengineered alternative to autologous vein grafts, aimed at improving outcomes in cases of limb-threatening vascular injuries where urgent revascularization is necessary and traditional grafts are not viable. The FDA's approval signifies a notable advancement in medical technology for patients requiring immediate vascular intervention. Following the announcement, Humacyte's stock price surged by approximately 61%, reflecting investor optimism about the product's potential impact in the medical field.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
No new competitors • 25%
1 new competitor • 25%
2 new competitors • 25%
3 or more new competitors • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
1-3 countries • 25%
4-6 countries • 25%
7-9 countries • 25%
10 or more countries • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
